Homepage / CARE & HOPE

CARE & HOPE

Our vision goes beyond technological advancement. We aim to bring care and hope closer to all.

 

gMendel®Care

With our gMendel®Care initiative, we aim to bring accurate diagnosis and fair, equal care opportunities closer to all families facing genetic disorders. We are working tirelessly to extend the our certification to the most common aneuploidies, microdeletion syndromes and the 3 diseases that comprise the Basic Carrier Testing for all ethnicities, a total of eight genetic disorders. Eventually, we are scaling up our technology to enable the detection of the 33 most prevalent genetic disorders in Europe.

 

Our vision is to fulfil as many New Born Screening panel requirements in as many countries as possible and include the gMendel®Test in national healthcare protocols. To this end, we are working with all possible stakeholders to promote systematic data collection and knowledge sharing of genetic disorders and contribute to the development of integrated healthcare services, regardless of social or financial inequalities of the patients.

 

gMendel®Hope

With gMendel®Hope, we aim to improve the outcomes from transplantation procedures, by introducing a novel screening technology for detection of epigenetic changes before and after the transplantation. There is emerging evidence that epigenetics plays an important role in health and disease. Epigenetic modifications may exert their effect independently or complementary to genetic variants and have the potential to modify gene expression. These modifications are dynamic, potentially heritable, and can be induced by environmental stimuli or chemical substances or medicines.

The identification of non-invasive and reliable epigenetic biomarkers for the prediction of allograft rejection and for monitoring immunosuppressive therapies is critical in the management of transplanted patients. Therefore, epigenetic mechanisms could contribute to establishing innovative diagnostic and predictive biomarkers, as well as ground-breaking therapies both for heart failure and heart transplantation rejection.

At the start of the project, we will focus on scientifically documented genetic factors that likely play role or affect the transplantation, for example, particular chromosomes, regions & genes.

 

We will then build a comprehensive Databank with various datasets, e.g., DNA from donors/recipients, success rate, medicines used, posology etc., aiming at improving the match between donors/recipients and the predictability of a successful transplant/surgery in a recipient. As the project progresses, and the Databank grows, the AI/ML algorithms will potentially identify spurious correlations between seemingly unrelated data sets. All in all, we will focus on the following:

  • Carry out epigenetic survey based on Whole Genome Sequencing (WGS) of the donors’ organ over time i.e., before transplantation, immediately after and periodically thereafter
  • Facilitate early detection of organ rejection by non-invasive methods, such as liquid biopsy and detecting presence of donor cfDNA in the recipient’s blood (due to infection).
  • Matching donors and recipients based on WGS biopsy samples.

Our ultimate goal is to be able to diagnose all known genetic disorders, nearly 8000, through Whole Genome via Targeted Sequencing.